What is rilvegostomig? An In-Depth Pharmacological Review
•
4 min read
In non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), rilvegostomig has demonstrated an objective response rate (ORR) of 61.8% [1.5.6]. This article explores the question: What is rilvegostomig and its role in modern oncology?
